Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma

NCT01436890 is registered in ClinicalTrials.gov with Glenmark Pharmaceuticals Ltd. India as lead sponsor.

NCT NCT01436890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01436890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
April 30, 2013
Enrollment
273 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

asthma